EZH2 and non-small cell lung carcinoma: Meanwhile, we designed, synthesized, screened, and evaluated a series of HIF‐1α and EZH2 dual‐targeting compounds, among which DYB‐03 showed good antitumor activity by inhibiting NSCLC cell migration, invasion, angiogenesis, and reverse drug resistance in vitro and in vivo.